Liraglutide Augments Weight Loss After Laparoscopic Sleeve Gastrectomy: a Randomised, Double-Blind, Placebo-Control Study.

Thakur U, Bhansali A, Gupta R, Rastogi A

Obesity surgery12 Jul 2020Cited by 42 (Europe PMC)

PMID32656729DOI10.1007/s11695-020-04850-4PepBankPUB-32656729

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In obese adults after laparoscopic sleeve gastrectomy, liraglutide did not significantly change percent total weight loss versus placebo at 24 weeks.
In plain wordsAfter sleeve gastrectomy, total weight loss with liraglutide was not significantly different from placebo.
Peptide
Liraglutide
Outcome
No significant changeTotal weight loss (%TWL) at 6 months
Study
n = 23
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
increasing doses from 0.6 mg/day to a maximum tolerated 3.0 mg/day (mean 1.41 mg/day) · subcutaneous · from 6 weeks until 6 months after surgeryAs given in this study (human).
Measurements
%TWL
28.2%
liraglutide
%TWL
23.2%
placebo
Source sentences
Summary
Patients in L-L group had %TWL of 28.2 ± 5.7 and %EWL of 58.7 ± 14.3 as compared with 23.2 ± 6.2 (p = 0.116) and 44.5 ± 8.6 (p = 0.043) in L-P group at 24 weeks, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants with BMI > 30 kg/m² undergoing LSG were randomised to receive either liraglutide (subcutaneous) in increasing does of 0.6 mg/day until maximum tolerated dose of 3.0 mg (L-L group) or placebo (L-P group) from 6 weeks post-operative until 6 months.
Report a problemFND-3265672901
02HumanRandomized controlled trialEfficacy outcome
In obese adults after laparoscopic sleeve gastrectomy, liraglutide increased percent excess body weight loss versus placebo at 24 weeks.
In plain wordsAfter sleeve gastrectomy, liraglutide led to more excess weight loss than placebo.
Peptide
Liraglutide
Outcome
IncreaseExcess body weight loss (%EWL) at 6 months
Study
n = 23
Comparator
Placebo
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
increasing doses from 0.6 mg/day to a maximum tolerated 3.0 mg/day (mean 1.41 mg/day) · subcutaneous · from 6 weeks until 6 months after surgeryAs given in this study (human).
Measurements
%EWL
58.7%
liraglutide
%EWL
44.5%
placebo
Source sentences
Summary
Patients in L-L group had %TWL of 28.2 ± 5.7 and %EWL of 58.7 ± 14.3 as compared with 23.2 ± 6.2 (p = 0.116) and 44.5 ± 8.6 (p = 0.043) in L-P group at 24 weeks, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants with BMI > 30 kg/m² undergoing LSG were randomised to receive either liraglutide (subcutaneous) in increasing does of 0.6 mg/day until maximum tolerated dose of 3.0 mg (L-L group) or placebo (L-P group) from 6 weeks post-operative until 6 months.
Report a problemFND-3265672902
03HumanRandomized controlled trialEfficacy outcome
In obese adults after laparoscopic sleeve gastrectomy, BMI fell in both groups, with no significant difference between liraglutide and placebo.
In plain wordsAfter sleeve gastrectomy, BMI fell with liraglutide and with placebo, with no significant difference between them.
Peptide
Liraglutide
Outcome
No significant changeBMI decrease
Study
n = 23
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
increasing doses from 0.6 mg/day to a maximum tolerated 3.0 mg/day (mean 1.41 mg/day) · subcutaneous · from 6 weeks until 6 months after surgeryAs given in this study (human).
Measurements
BMI decrease
11.7 kg/m2
liraglutide
BMI decrease
9.5 kg/m2
placebo
Source sentences
Summary
BMI decreased by 11.7 ± 3.5 in L-L group compared with 9.5 ± 4.0 in L-P group (p = 0.287).
1 context sentence(design, population, supporting numbers)
Summary · context
Participants with BMI > 30 kg/m² undergoing LSG were randomised to receive either liraglutide (subcutaneous) in increasing does of 0.6 mg/day until maximum tolerated dose of 3.0 mg (L-L group) or placebo (L-P group) from 6 weeks post-operative until 6 months.
Report a problemFND-3265672903
04HumanRandomized controlled trialEfficacy outcome
In obese adults with diabetes or pre-diabetes after sleeve gastrectomy, all liraglutide patients had resolution of dysglycemia versus 50% with placebo.
In plain wordsAfter sleeve gastrectomy, all liraglutide patients with diabetes or pre-diabetes had normal glucose, compared with half of those on placebo.
Peptide
Liraglutide
Outcome
IncreaseResolution of dysglycemia (diabetes or pre-diabetes)
Study
n = 23
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
increasing doses from 0.6 mg/day to a maximum tolerated 3.0 mg/day (mean 1.41 mg/day) · subcutaneous · from 6 weeks until 6 months after surgeryAs given in this study (human).
Measurements
resolution of dysglycemia
50%
placebo
Source sentences
Summary
All patients with diabetes or pre-diabetes had resolution of dysglycemia in the L-L group as compared with 50% in L-P group.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants with BMI > 30 kg/m² undergoing LSG were randomised to receive either liraglutide (subcutaneous) in increasing does of 0.6 mg/day until maximum tolerated dose of 3.0 mg (L-L group) or placebo (L-P group) from 6 weeks post-operative until 6 months.
Report a problemFND-3265672904
05HumanRandomized controlled trialEfficacy outcome
In obese adults after sleeve gastrectomy, liraglutide did not significantly change the resolution of other obesity-related comorbidities versus placebo at 24 weeks.
In plain wordsAfter sleeve gastrectomy, liraglutide made no significant difference to other weight-related health problems compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeResolution of other obesity-related comorbidities
Study
n = 23
Comparator
Placebo
Outcome group
Cardiometabolic risk factors · Metabolic and weight
Studied dose
increasing doses from 0.6 mg/day to a maximum tolerated 3.0 mg/day (mean 1.41 mg/day) · subcutaneous · from 6 weeks until 6 months after surgeryAs given in this study (human).
Source sentences
Summary
However, there was no significant difference in resolution of other obesity-related comorbidities between two groups at 24-week follow-up.
1 context sentence(design, population, supporting numbers)
Summary · context
Participants with BMI > 30 kg/m² undergoing LSG were randomised to receive either liraglutide (subcutaneous) in increasing does of 0.6 mg/day until maximum tolerated dose of 3.0 mg (L-L group) or placebo (L-P group) from 6 weeks post-operative until 6 months.
Report a problemFND-3265672905

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 4NCT06132477

Impact GLP-1 Agonists Following Bariatric

University of Missouri-Columbian = 1501 Feb 2024 to est. Jul 2030

Morbid Obesity · Metabolic Syndrome · Diabetes Mellitus · Hypertension · Obstructive Sleep Apnea of Adult

Trial page ClinicalTrials.govUpdated 21 Oct 2026

Status unknownNot applicableNCT05285397

Effect of Liraglutide on Weight Loss in Patients Who Have Undergone Revisional Bariatric Surgeries.

General Committee of Teaching Hospitals and Institutes, Egyptn = 60est. 10 Mar 2022 to est. Sept 2022

Morbid Obesity

Trial page ClinicalTrials.govUpdated 17 Mar 2022

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.